{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:36:57Z","timestamp":1791329817487,"version":"4.3.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.neurol.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T05:46:27Z","timestamp":1462340787000},"page":"256-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Neuromyelitis optica spectrum disorder (NMOSD): A new concept"],"prefix":"10.1016","volume":"172","author":[{"given":"J.","family":"de S\u00e8ze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2016.03.003_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1191\/1352458503ms947oa","article-title":"Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis","volume":"9","author":"de Seze","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2016.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2016.03.003_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurol.2016.03.003_bib0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ana.22121","article-title":"Intractable vomiting as the initial presentation of neuromyelitis optica","volume":"68","author":"Apiwattanakul","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1212\/WNL.0b013e3182343377","article-title":"Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica","volume":"77","author":"Iorio","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2016.03.003_bib0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0065","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/archneur.65.7.920","article-title":"OCT Optical coherence tomography in neuromyelitis optica","volume":"65","author":"de Seze","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0070","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0075","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0085","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2016.03.003_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"MOG pediatricClinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2016.03.003_bib0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2016.03.003_bib0110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jnnp.2007.143263","article-title":"Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4","volume":"79","author":"Jarius","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2016.03.003_bib0115","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Magana","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"IgIVRole of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2016.03.003_bib0130","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2016.03.003_bib0140","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-beta exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0150","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2016.03.003_bib0165","doi-asserted-by":"crossref","DOI":"10.1177\/1352458516630823","article-title":"False positivity of anti-aquaporin-4 antibodies in natalizumab-treated patients","author":"Cohen","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2016.03.003_bib0170","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0175","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0185","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0190","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0195","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0200","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0205","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0210","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neurmyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2016.03.003_bib0215","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0220","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as a first line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0225","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0230","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7224\/1537-2073-2.4.43","article-title":"Treatment of Devic's Disease With Methotrexate and Prednisone","volume":"2","author":"Minagar","year":"2000","journal-title":"Int J MS Care"},{"issue":"8","key":"10.1016\/j.neurol.2016.03.003_bib0240","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2016.03.003_bib0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","article-title":"Intermittent plasmapheresis prevents recurrence in neuromyelitis optica","volume":"13","author":"Miyamoto","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.neurol.2016.03.003_bib0250","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1586\/1744666X.2013.839944","article-title":"Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?","volume":"9","author":"de Seze","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.neurol.2016.03.003_bib0255","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","article-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromylitis optica","volume":"1","author":"Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neurinflammation"},{"key":"10.1016\/j.neurol.2016.03.003_bib0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","article-title":"Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica","volume":"68","author":"Matiello","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler J"},{"issue":"6","key":"10.1016\/j.neurol.2016.03.003_bib0270","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0275","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"IL-6 Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.03.003_bib0280","article-title":"IL-6 long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","author":"Ringelstein","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0285","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"IL-6 Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2016.03.003_bib0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378715300199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378715300199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T13:52:28Z","timestamp":1536760348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378715300199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":58,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0035378715300199"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2016.03.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorder (NMOSD): A new concept","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}